Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen
机构：[1]Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA;[2]Helsinn Therapeut Inc, Iselin, NJ USA;[3]Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA;[4]Helsinn Healthcare SA, Lugano, Switzerland;[5]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China中山大学肿瘤防治中心
第一作者机构：[1]Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA;[2]Helsinn Therapeut Inc, Iselin, NJ USA;[3]Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA;[4]Helsinn Healthcare SA, Lugano, Switzerland;[5]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Roeland Eric,Binder Gary,Ma Joseph,et al.Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen[J].JOURNAL OF CLINICAL ONCOLOGY.2017,35(31):-.doi:10.1200/JCO.2017.35.31_suppl.120.
APA：
Roeland, Eric,Binder, Gary,Ma, Joseph,Lanzarotti, Corinna&Zhang, Li.(2017).Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.JOURNAL OF CLINICAL ONCOLOGY,35,(31)
MLA：
Roeland, Eric,et al."Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen".JOURNAL OF CLINICAL ONCOLOGY 35..31(2017):-
医学